SCARB1 and T-cell leukemia: DiI HDL NP treatment of Jurkat cells, a SCARB1-negative T cell leukemia/lymphoma cell line, did not result in increased fluorescent signal over baseline (Fig. S1, C), confirming that the HDL NPs target SCARB1 in B cell lymphoma.